How did Abbott avoid generic fenofibrate competition?

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.652, 2012-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is Generic Prescribing Acceptable in Epilepsy?

By Besag F.M.C.

Drug Safety, Vol. 23, Iss. 3, 2000-09 ,pp. : 173-182

Adis International

Access to resources Recommend Favorite

Generic antiretrovirals − a controversial option?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 670, 2013-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Generic Drug Regulation in the US Under the Hatch-Waxman Act: A Balance Between Competition and Innovation or Confusion and Intrigue?

By Milne C-P. Cairns C.

Pharmaceutical Development and Regulation, Vol. 1, Iss. 1, 2003-01 ,pp. : 11-27

Adis International

Access to resources Recommend Favorite

The Generic Alternative in Schizophrenia: Opportunity or Threat?

By Philippe Nuss

CNS Drugs, Vol. 18, Iss. 12, 2004-01 ,pp. : 769-775

Adis International

Access to resources Recommend Favorite

Are Irish eyes smiling on generic substitution, reference pricing?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 607, 2010-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite